Chagnovich has
identified specific molecular targets for bone formation, and expanded
Velcura's bone growth technologies. "As Director of Research, he will play an
important role in our taking this compound to clinical trials in 2006," said
Dr.8 million from the National
Institutes of Health. Dharmacon's SMARTpool siRNA reagents,
innovative mixtures of four highly functional, individual siRNAs, minimize
screening costs and guarantee potent gene silencing while limiting off-target
effects and reducing the likelihood of false-positive and false-negative
results.

evaluated embnet

, the world's
leading supplier of innovative RNA and RNA interference (RNAi) research
products, today announced the completion of the world's first genome-wide,
short-interfering RNA (siRNA) library. Marshall, Ph.
Dharmacon is a company within the Fisher Biosciences group, a unit of Fisher
Scientific International Inc. Our location in Singapore also
provides us with an excellent base to reach India and the Asia Pacific
markets for commercial applications. Those statements include
statements regarding the intent, belief or current expectations of
Healtheuniverse, Inc.

botany curated

His leadership in that
effort and other roles he undertook at Velcura made Danny a natural choice for
this position. He also was a postdoctoral fellow at
the Skirball Institute for Biomedical Research in New York City.

Available Topic Expert(s): For information on the listed expert(s), click
appropriate link.prnewswire., Dharmacon, Inc.D., vice president
of Technology and Business Development for the Fisher Biosciences Group.

botany genamics

- Library Targets 21,000 Human Genes and Includes Over 100,000 siRNA Reagents
Using Industry-Leading SMARTselection(TM) and SMARTpool (R) Technologies -

- Has the Potential to Revolutionize Functional Genomics and Drug-Discovery
Research -

LAFAYETTE, Colo.
Developed using Dharmacon 's proprietary SMARTselection(TM) and
SMARTpool(R) technologies, it is designed to dramatically decrease the time
and cost needed for high-throughput functional genomic studies, while
providing scientists with new capabilities to conduct research that was
formerly not feasible.

About Dharmacon
Dharmacon is the world's leading provider of reliable, high quality RNA
oligonucleotides, small interfering RNA (siRNA) and related RNA-interference
(RNAi) products and technologies.

embnet ordinated

"We
believe that the release of this genome-wide siRNA collection represents a
fundamental advance in the capabilities available to biological researchers
and will forever change medical research , by making it possible for scientists
to determine the function of every human gene. Marshall continued , "Until now, biological researchers seeking to
elucidate the functions of genes were limited to studies in worms and fruit
flies, or to small-scale studies of human gene function. The availability of five gene-silencing reagents per gene also
provides researchers the opportunity for independent validation of gene
silencing effects. Dharmacon's
proprietary SMARTselection(TM) and SMARTpool(R) technologies result in potent
and specific gene-silencing agents that can accelerate life-science research
and drug discovery. Singapore also has the strongest
intellectual property (IP) protection rules in the region, and was ranked
as the most IP-protective country in Asia in 2003 by the Political and
Economic Risk Consultancy, Ltd (PERC). "We will also take advantage of hiring
from an outstanding talent base of scientists in Singapore and the
opportunity to forge collaborative agreements with local firms and academic
groups through our presence in Biopolis. Situated in the south-western part of
Singapore, the Biopolis is near both the National University of Singapore
and the National University Hospital.

biozone zoology

What's more, Dr. Chagnovich earned his Ph. biotechnology company focused on developing drugs that stimulate
bone formation, Velcura Therapeutics(R), Inc.
"We are proud to announce Dharmacon's completion of the first complete
human genome-wide library, a milestone event for both the biomedical research
community and for Dharmacon," said William S.

PRESS RELEASE Healtheuniverse to Establish Research and Development Base for Its Regenerative Medicine and Stem Cell Applications in Biopolis Singapore

(OTC: HLUN), a
biotechnology development firm specializing in the development and
commercialization of biopharmaceutical and biomedical products, announced
today that it will establish the company's research and develop base for
regenerative medicine and stem cell applications in Biopolis, Singapore.

Healtheuniverse intends to locate substantially all research and
development operations in Biopolis, Singapore to take advantage of its
world-class R&D environment, state-of -the art facilities, and the
availability of shared facilities and services.

"Our facilities in Singapore will be state-of-the-art, and we feel that the
government is doing its utmost to minimize any obstacles and hindrances to
our biomedical research efforts," stated Dr.

bioscience ordinated

The
U. Prospective investors are
cautioned that any such forward-looking statements are not guarantees of
future performance and involve risks and uncertainties, and that actual
results may differ materially from those contemplated by such
forward-looking statements.

arboretums bioinformatics

Dr."
Dharmacon's siARRAY whole genome-wide siRNA library includes more than
100,000 siRNA reagents targeting over 21,000 human genes contained in the NCBI
RefSeq database.

biome knowledgebase

Chagnovich joined Velcura in 2003 as Senior Scientist, Bioinformatics ., President and CEO of Velcura Therapeutics(R),
Inc. "The custom DNA microarray that Dr. Chagnovich is now working on Velcura's new orally
available compound that both inhibits bone loss and stimulates bone
formation," explained Dr.prnewswire. Now for the first
time, scientists will be able to conduct unbiased high-throughput, genome-wide
gene-silencing studies in human cell lines.com or call 303-604-9499.com/

Safe Harbor Statement

This press release contains statements, which may constitute
"forward-looking statements" within the meaning of the Securities Act of
1933 and the Securities Exchange Act of 1934, as amended by the Private
Securities Litigation Reform Act of 1995.

arboretums bioscience

ANN ARBOR, Mich., Velcura Therapeutics(R), Inc.
Prior to joining Velcura, Dr.
http: //profnet.D. (NYSE: FSH). Singapore meets stringent international and
local regulatory requirements that ensure our research completed at
Biopolis is respected and credible in every market in the world .

bioresearch botany

, a Japanese pharmaceutical company, plans to
begin clinical trials in 2006 of a new drug the two companies have found to be
effective in animal models of osteoporosis.

biozone netbook

Velcura Therapeutics(R) Inc . a Company Dedicated to Fighting Bone Disease Promotes Daniel Chagnovich Ph.D. to Director of Research Operations

D. Long. These qualities are especially important for
high-throughput-screening applications , where both functionality and cost
effectiveness are essential.

herbaria biochemistry

Long. There he was
honored with a National Institutes of Health (NIH) National Research Service
Award and as a Howard Hughes Medical Institute Research Associate.

About Velcura Therapeutics(R), Inc.3 million in funding from the Michigan Life
Sciences Corridor in 2002 and more than $3.
Michael W. The siARRAY(R) genome -wide library is
the first complete library targeting genes across the entire human genome. A SMARTpool siRNA reagent and four individual siRNAs are
available for each unique human gene.

Government support and a pro-business environment will benefit both our
US-based and Singapore-based operations . The five biomedical research
institutes of A*STAR, BioInformatics Institute (BII), the Bioprocessing
Technology Institute (BTI), the Genome Institute of Singapore (GIS), the
Institute of Molecular and Cell Biology (IMCB) and the Institute of
Bioengineering & Nanotechnology (IBN) are co-located at the Biopolis. Important factors currently known to management
that could cause actual results to differ materially from those in
forward-looking statements include fluctuation of operating results , the
ability to compete successfully and the ability to complete
before-mentioned transactions .

zoology biosciences

The company's advanced siRNA modification technologies
further enhance silencing specificity, stability , and in vivo performance. is a biotechnology development firm specializing in
the development and commercialization of Biopharmaceutical and Biomedical
products. More information on Healtheuniverse is available online at
http://healtheuniverse.

netbook evaluated

has promoted Daniel Chagnovich, Ph.
At Velcura , he has used bioinformatics analyses to characterize the molecular
events underlying human bone formation .D.S.com/ud_public.

Contacts:
Dharmacon:
Julia Kendall
Manager, Marketing Communications
303-604-9499

Media:
Barbara Lindheim
GendeLLindheim BioCom Partners
212-918-4650

About HEALTHeUNIVERSE, Inc.

biosciences genamics

Long, Ph.D. Dr . Velcura which has a license agreement with Nippon
Chemiphar Co. For more information about
Dharmacon products and services visit http://www.

biochemie embnet

to Director of Research Operations. Chagnovich worked as a scientist at Pfizer's
Global Research and Development Center in Ann Arbor, where he used
bioinformatics tools to evaluate the human genome and identify novel genes in
support of its cardiovascular and proteomics research efforts. Long, Ph.D.
Healtheuniverse, Inc."

About Biopolis Singapore

Biopolis is a biomedical research hub where researchers from the public and
private sectors are co-located.

biome biochemistry

Chagnovich helped create makes it
possible for us to consolidate industry knowledge and quickly identify drug
leads for the development of bone disease therapies. in 1996 at Northwestern University Medical
School in Chicago, after receiving a bachelor's degree in Biochemistry from
the University of California, Riverside. (Chemiphar), Ltd. For more information, visit
http://www.jsp?userid=342569
Daniel Chagnovich, Ph.

Dharmacon's Completion of First Human Genome-Wide siRNA Library Signals New Era in Life-Science Research

We intend to cut R&D costs
significantly while accelerating our development and commercialization
timeline., and members of their management as well as the
assumptions on which such statements are based.

bioscience netbook

com/ud_public. The company undertakes no obligation to
update or revise
forward-looking statements to reflect changed assumptions, the statements
to reflect changed assumptions, the occurrence of unanticipated events or
changes to future operating results .

zoology biochemistry

S. biotechnology company focuses on developing drugs that stimulate bone
formation.
A U.com. Availability of Dharmacon's complete human genome-wide
siRNA library is expected to significantly accelerate drug discovery and
development, and it also has the potential to increase scientists'
understanding of fundamental disease mechanisms."
Dr. Dharmacon's siGENOME(TM), a comprehensive and flexible
siRNA collection, offers guaranteed silencing reagents for all unique human
mouse and rat genes. By co-locating with the public research institutes onsite we
feel it will provide economies of scale to optimize the use of high end
resources such as X-ray crystallography, nuclear magnetic resonance,
electron microscopy, DNA sequencing and other necessary equipment without
incurring the expense and time needed to purchase this equipment.Vipul Dev, MD, Chief Executive
Officer of Healtheuniverse, Inc. We develop and provide early stage project initiation,
financing, product commercialization and development of patented and
proprietary biopharmaceutical, biomedical, nutraceutical , and cosmeceutical
products.

microbiology reactome

Chagnovich directed efforts that led to
the identification of the 1,250 human genes associated with bone formation,"
said Michael W. using human bone cells, grows
human bone outside the body and analyzes this process to develop novel
therapies for osteoporosis and other bone diseases. Based in Ann Arbor,
Mich. Dharmacon's whole genome
collection enables researchers to rapidly and efficiently generate accurate
information about gene pathways and to identify new genes and gene functions.dharmacon.

HEALTHeUNIVERSE, Inc.

biochemistry histology

Dr.
"During the past two years, Dr.velcura.
http://profnet. The US-Singapore Free Trade
Agreement (USSFTA) brings patent registration and protection in-line with
our US-based requirements.

biologist biozone

biologist reactome

evaluated biochemistry

, the company received $3.jsp?userid=342623

Using its core expertise in chemistry,
biology, bioinformatics and production, Dharmacon has developed
industry-leading siRNA design, chemical modification, and delivery
technologies for maximizing the efficiency of gene silencing.